<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COPD exacerbations: Prognosis, discharge planning, and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COPD exacerbations: Prognosis, discharge planning, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COPD exacerbations: Prognosis, discharge planning, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1670438302"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An exacerbation of chronic obstructive pulmonary disease (COPD) is defined as "an event characterized by dyspnea and/or cough and sputum that worsens over ≤14 days, which may be accompanied by tachypnea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways" by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a report produced by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO) [<a href="#rid1">1,2</a>]. This generally includes an acute change in one or more of the following cardinal symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Cough increases in frequency and severity</p><p class="bulletIndent1"><span class="glyph">●</span>Sputum production increases in volume and/or changes character</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea increases</p><p></p><p>The prognosis after a COPD exacerbation and strategies for prevention of future exacerbations will be discussed here. The risk factors, clinical manifestations, diagnosis, and management of COPD exacerbations are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/122144.html" rel="external">"COPD exacerbations: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a> and  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H1074706316"><span class="h1">PROGNOSIS AFTER AN EXACERBATION</span><span class="headingEndMark"> — </span>Exacerbations of COPD are associated with increased morbidity and mortality [<a href="#rid1">1,3-5</a>]. Individuals who have experienced a single moderate COPD exacerbation, compared with those without exacerbation, have an increased risk of respiratory and all-cause mortality (hazard ratios 2.98 [95% CI 1.14-7.83] and 1.34 [95% CI 0.79-2.29], respectively) [<a href="#rid4">4</a>].</p><p>A number of factors influence mortality following hospital discharge after an exacerbation of COPD, including older age, the severity of the underlying COPD, requirement for long-term oxygen at discharge, presence of comorbidities (eg, cardiovascular disease or lung cancer), and the presence of <em>Pseudomonas aeruginosa</em> in the patient's sputum, as described in the following studies [<a href="#rid6">6-14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients hospitalized with a COPD exacerbation, in-hospital mortality ranges from three to nine percent [<a href="#rid12">12-14</a>]. In a separate study of patients who required noninvasive ventilation, in-hospital mortality was 11 percent [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 260 patients admitted with a COPD exacerbation, the one year mortality was 28 percent [<a href="#rid9">9</a>]. Independent risk factors for mortality were age, male sex, prior hospitalization for COPD, arterial tension of carbon dioxide (PaCO<sub>2</sub>) ≥45 mmHg (6 kPa), and blood urea &gt;8 mmol/L (BUN 22 mg/dL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients hospitalized for a COPD exacerbation who have <em>Pseudomonas aeruginosa</em> in their sputum have a higher risk of mortality at three years than those without (59 versus 35 percent; HR 2.33, 95% CI 1.29-3.86), independent of age, comorbidity, or COPD severity [<a href="#rid10">10</a>].</p><p></p><p>Even if the COPD exacerbation resolves, many patients never return to their baseline level of health [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2205821911"><span class="h1">COMPREHENSIVE DISCHARGE PLANNING</span><span class="headingEndMark"> — </span>For patients who have required hospitalization for a COPD exacerbation, formal criteria for discharge and a comprehensive discharge plan may help to reduce readmissions and recurrent exacerbations, although supportive data are mixed [<a href="#rid1">1,16-18</a>]. Nonetheless, the following discharge planning steps appear sensible and are consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/2790.html" rel="external">"Hospital discharge and readmission"</a>.)</p><p class="headingAnchor" id="H1438093547"><span class="h2">Criteria for discharge</span><span class="headingEndMark"> — </span>Criteria for discharge generally depend on sufficient improvement in the manifestations of COPD such that the patient’s condition has stabilized, and frequent nebulizer treatments are no longer required. If the patient is near their prehospital baseline, discharge to home is likely appropriate. However, some patients no longer require hospital-level care but are unable to manage at home due to frailty or severe exercise intolerance; for these patients, a period of inpatient rehabilitation may be more suitable. Patients requiring nocturnal noninvasive ventilation may benefit from a rehabilitation hospital stay. (See  <a class="medical medical_review" href="/z/d/html/2790.html" rel="external">"Hospital discharge and readmission", section on 'Determining the post-discharge site of care'</a>.)</p><p>When deciding whether a patient can be discharged to home, the patient’s ability to manage activities of daily living (ADLs) at home should be assessed along with the need for assistive devices such as a walker, elevated toilet seat, bedside commode, or shower chair. (See  <a class="medical medical_review" href="/z/d/html/3009.html" rel="external">"Comprehensive geriatric assessment", section on 'Activities of daily living'</a>.) </p><p class="headingAnchor" id="H3891135941"><span class="h2">Discharge to home checklist</span><span class="headingEndMark"> — </span>A number of issues pertaining to COPD exacerbations in particular and hospitalizations in general must be assessed as part of discharge planning, such as: the transition from hospital to home (eg, oxygen en route, stairs to climb), the patient’s ability to obtain and self-administer medications, meal preparation and self-feeding, and the need for visiting nurse, in-home services, and hospice.</p><p>A checklist can ensure that important steps to enable a smooth transition to home are not overlooked. Checklists may be general  (<a class="graphic graphic_table graphicRef54279" href="/z/d/graphic/54279.html" rel="external">table 1</a>) or specific to COPD  (<a class="graphic graphic_form graphicRef130525" href="/z/d/graphic/130525.html" rel="external">form 1</a>). Components that are thought to improve discharge success include the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Explain diagnosis and planned postdischarge therapy with patient/caregiver; ensure understanding and agreement with the regimen</p><p class="bulletIndent1"><span class="glyph">●</span>Review with patient the technique(s) of all inhaler devices that will be used at discharge and assess their technique</p><p class="bulletIndent1"><span class="glyph">●</span>Review management plans for comorbidities (eg, heart failure, coronary heart disease, arrhythmia, lung cancer screening, sleep-related breathing disorders, metabolic syndrome, anxiety, depression)</p><p class="bulletIndent1"><span class="glyph">●</span>Ensure that patient understands written and verbal directions for withdrawal of acute medications (eg, antibiotics, systemic glucocorticoids) used to treat exacerbation</p><p class="bulletIndent1"><span class="glyph">●</span>Confirm that patient has received appropriate vaccinations for seasonal influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and <em>S. pneumococcus </em>(See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Provide smoking cessation education and medication to patients who smoke</p><p class="bulletIndent1"><span class="glyph">●</span>Assess need for supplemental oxygen and prescribe if indicated; ensure that supplemental oxygen will be available for transfer to home and in the home before the patient arrives</p><p class="bulletIndent1"><span class="glyph">●</span>Assess need for home nebulizer treatments and arrange for nebulizer if needed</p><p class="bulletIndent1"><span class="glyph">●</span>Arrange for out-patient pulmonary rehabilitation program, as appropriate</p><p class="bulletIndent1"><span class="glyph">●</span>Advise patient regarding any pending test results or planned follow-up testing (eg, lung cancer screening)</p><p class="bulletIndent1"><span class="glyph">●</span>Confirm follow-up visits at approximately one and four weeks, and as indicated</p><p></p><p>Patients who have a new prescription for long-term oxygen typically need additional instruction on the use of oxygen delivery systems (eg, tanks, concentrators, portable systems) and safe practices regarding oxygen tubing as a tripping hazard and avoiding exposure to open flames (see  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1442.html" rel="external">"Portable oxygen delivery and oxygen conserving devices"</a>). Such patients should be reassessed two to three months after discharge regarding whether supplemental oxygen is still needed and, if so, at what dose.</p><p class="headingAnchor" id="H4098420497"><span class="h2">Palliative care planning</span><span class="headingEndMark"> — </span>The disease trajectory in COPD is heterogenous and ranges from gradual worsening of exercise tolerance and oxygenation to a sudden and unanticipated end-of-life. Given the difficulties in predicting the clinical course, an exacerbation requiring hospitalization, particularly one requiring intensive care, creates an opportunity to discuss a palliative care consultation. Criteria for considering a palliative care referral are listed in the table  (<a class="graphic graphic_table graphicRef103284" href="/z/d/graphic/103284.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">"Palliative care for adults with nonmalignant chronic lung disease", section on 'What are the indications for a palliative care consultation?'</a>.)</p><p>The primary care provider or pulmonary specialist can raise the possibility of a palliative care approach and obtain a palliative care consultation, if needed. Important components of palliative care include exploring the patient’s understanding about their illness and prognosis, assessing and managing symptoms, discussing goals of care and advance care planning, coordinating care, and helping to plan end-of-life care, including determining the need and timing of hospice care  (<a class="graphic graphic_table graphicRef103286" href="/z/d/graphic/103286.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">"Palliative care for adults with nonmalignant chronic lung disease"</a>.)</p><p>For patients with advanced COPD, it may be reasonable to discuss hospice care at home. Disease specific guidelines are listed in the table and discussed separately  (<a class="graphic graphic_table graphicRef61282" href="/z/d/graphic/61282.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">"Palliative care for adults with nonmalignant chronic lung disease"</a> and  <a class="medical medical_review" href="/z/d/html/2200.html" rel="external">"Hospice: Philosophy of care and appropriate utilization in the United States"</a>.)</p><p class="headingAnchor" id="H869263960"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H2594273643"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Several measures can reduce the frequency of COPD exacerbations including the following [<a href="#rid1">1,19-21</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span>Smoking cessation (see  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Proper use of medications (including inhaler technique)  (<a class="graphic graphic_table graphicRef103303" href="/z/d/graphic/103303.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef72362" href="/z/d/graphic/72362.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef51020" href="/z/d/graphic/51020.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef93600" href="/z/d/graphic/93600.html" rel="external">table 8</a>) (see  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Vaccination against seasonal influenza (see  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Pneumococcal vaccination  (<a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 1</a>) (see  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Vaccination against respiratory syncytial virus (suspected benefit, which will be revisited as data emerge) (see  <a class="medical medical_review" href="/z/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Immunization'</a>)</p><p></p><p class="headingAnchor" id="H4134184139"><span class="h2">Pulmonary rehabilitation</span><span class="headingEndMark"> — </span>Pulmonary rehabilitation has a number of benefits; it significantly reduces future hospital admissions and mortality and improves exercise tolerance and quality of life, compared with usual community care [<a href="#rid22">22</a>]. After a COPD exacerbation, we encourage patients to participate in a pulmonary rehabilitation program, if they have not yet done so. The optimal timing for initiating pulmonary rehabilitation after a COPD exacerbation has not been determined and likely needs to be individualized; patients need to have recovered sufficiently to maximize the benefits of exercise training. (See  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation", section on 'Benefits'</a> and  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation", section on 'Setting'</a>.)</p><p class="headingAnchor" id="H3936923063"><span class="h2">Physical activity</span><span class="headingEndMark"> — </span>While pulmonary rehabilitation programs are preferred, if one is not available, physical activity (exercising two to three times per week for 30 minutes to a level that causes mild shortness of breath) may reduce hospitalizations for COPD exacerbations based on observational data [<a href="#rid19">19</a>]. Further study is needed on alternatives to pulmonary rehabilitation programs in under-resourced settings.</p><p class="headingAnchor" id="H2411728791"><span class="h2">Optimizing medications for COPD</span><span class="headingEndMark"> — </span>A number of medications for COPD reduce the frequency of COPD exacerbations. A personalized approach to medication selection should be based on the patient’s severity of COPD symptoms and exacerbation frequency, noting that certain medications may be of greater benefit for some patients than others [<a href="#rid1">1</a>]. As an example, inhaled glucocorticoids reduce exacerbations in patients with a history of exacerbations but are not likely to be of benefit in patients with low blood eosinophils. (See  <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">"Stable COPD: Follow-up pharmacologic management", section on 'Persistent exacerbations with or without dyspnea'</a>.)</p><p>The selection among these medications and their efficacy in reducing exacerbations are reviewed separately  (<a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef122795" href="/z/d/graphic/122795.html" rel="external">table 9</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Long-acting muscarinic antagonists (LAMA). (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Long-acting muscarinic antagonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-acting beta-agonists (LABA). (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Long-acting beta-agonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LAMA-LABA combination inhalers. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Use of dual bronchodilator therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LABA-glucocorticoid combination inhalers. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Alternative approaches'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LAMA-LABA-glucocorticoid combination inhalers. (See  <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">"Stable COPD: Follow-up pharmacologic management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">Roflumilast</a>, an oral PDE-4 inhibitor, reduces the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of frequent COPD exacerbations (eg, at least two per year or one requiring hospitalization). (See  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Phosphodiesterase-4 inhibitors (Roflumilast)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral thiol derivatives, such as <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC), erdosteine, and carbocysteine, are used to thin secretions in patients with bothersome sputum production, but studies have not demonstrated a reduction in exacerbations. (See  <a class="medical medical_review" href="/z/d/html/1456.html" rel="external">"Role of mucoactive agents and secretion clearance techniques in COPD", section on 'Thiols and thiol derivatives'</a> and  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Mucoactive agents'</a>.)</p><p></p><p>For patients whose medications are changed during a hospitalization, it is important to reevaluate discharge medications at office visits in the next one to four weeks. This is a good time to consolidate inhaled medications into a single inhaler if possible or to select inhaler devices that use the same technique. The proper technique should be reviewed for every inhaler that the patient is using. If the patient has poor inspiratory flow or is unable to demonstrate proper technique, nebulized medication from the appropriate class can be substituted: LAMAs (<a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">revefenacin</a>), LABAs (<a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> and <a class="drug drug_general" data-topicid="9433" href="/z/d/drug information/9433.html" rel="external">arformoterol</a>), and glucocorticoid (<a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>).</p><p class="headingAnchor" id="H2692717375"><span class="h2">Prophylactic azithromycin</span><span class="headingEndMark"> — </span>For patients with recurrent exacerbations (≥2 per year) despite optimal therapy (eg, long-acting bronchodilators with or without inhaled glucocorticoids, smoking cessation, vaccinations, and pulmonary rehabilitation), prophylactic <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> may reduce the frequency of exacerbations. The dosing, potential adverse effects, and evidence in support of prophylaxis with azithromycin are described separately. (See  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease", section on 'Prophylactic macrolides'</a> and  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Macrolides and other chronic antibiotic therapy'</a>.) </p><p class="headingAnchor" id="H1638067358"><span class="h2">GLP-1 receptor agonists and SGLT-2 inhibitors, for diabetic patients</span><span class="headingEndMark"> — </span>Glucagon-like peptide 1 (GLP-1) receptor agonists (eg, <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a>) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors (eg, <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a>) may offer some protection against exacerbations in patients with diabetes and COPD, although further data are needed to confirm these findings.</p><p class="bulletIndent1"><span class="glyph">●</span>In one population-based cohort study of patients with COPD and new initiation of an antihyperglycemic agent, 1252 patients who began GLP-1 receptor agonists and 2956 patients who began SGLT-2 inhibitors were matched with similar patients who received sulfonylureas instead [<a href="#rid23">23</a>]. Compared with patients receiving sulfonylureas, those on GLP-1 receptor agonists were less likely to be hospitalized for COPD exacerbations (3.5 versus 5.0 percent of patients per year [HR 0.7, 95% CI 0.49-0.99]); similar results were seen for those on SGLT-2 inhibitors (2.4 versus 3.9 percent per year [HR 0.62, 95% CI 0.48-0.81]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate retrospective database analysis, 1642 patients with COPD initiating new oral agents for DM were evaluated over six months following treatment initiation [<a href="#rid24">24</a>]. The adjusted incidence rates of moderate or severe exacerbations were improved with GLP-1RA inhibitors compared with dipeptidyl peptidase-4 inhibitors (incidence rate ratio [IRR] 0.67, 95% CI 0.49-0.93) or sulfonylureas (IRR 0.49, 95% CI 0.37-0.62); there was no difference compared with SGLT-2 inhibitors.</p><p></p><p>The mechanism underlying the potential benefits of these agents is unclear. GLP-1 receptor agonists have been shown to reduce inflammation and result in weight loss, with improvements in lung function in small clinical trials [<a href="#rid25">25,26</a>]. SGLT-2 inhibitors decrease endogenous carbon dioxide production via metabolic effects and appear to decrease risk of pneumonia based on meta-analyses of cardiovascular trials [<a href="#rid27">27</a>].</p><p>Future trials are needed to determine whether use of GLP-1 receptor agonists or SGLT-2 inhibitors are preferable to other antihyperglycemic agents in patients with DM and risk for COPD exacerbations.</p><p class="headingAnchor" id="H2526119679"><span class="h2">Noninvasive ventilation</span><span class="headingEndMark"> — </span>For patients who require noninvasive ventilation (NIV) during a hospitalization for a COPD exacerbation and who remain hypercapnic, nocturnal NIV at home significantly reduces the risk of rehospitalization. (See  <a class="medical medical_review" href="/z/d/html/1453.html" rel="external">"Nocturnal ventilatory support in COPD"</a>.)</p><p class="headingAnchor" id="H164523262"><span class="h2">Vitamin D supplementation</span><span class="headingEndMark"> — </span>Adhering to current guidelines regarding vitamin D supplementation in patients with a 25-hydroxyvitamin D level &lt;20 or 30 ng/mL (50 or 75 nmol/L) reduces COPD exacerbations in addition to benefits in reducing falls and fractures (see  <a class="medical medical_review" href="/z/d/html/2033.html" rel="external">"Overview of vitamin D"</a>). While randomized trials were conflicting [<a href="#rid28">28-31</a>], a systematic review and meta-analysis used individual patient data from three of the four randomized trials to examine the role of supplementation in patients with 25-hydroxyvitamin D (25[OH]D) levels &lt;25 nmol/L [<a href="#rid32">32</a>].</p><p>In the meta-analysis, vitamin D supplementation did not reduce the rate of moderate-to-severe COPD exacerbations overall, but a prespecified subgroup analysis revealed protective effects in patients with a baseline serum 25[OH]D level &lt;10 ng/mL (&lt;25 nmol/L; adjusted rate ratio 0.55, 95% CI 0.36-0.84). The trial that was not included in the analysis had separately found a benefit to vitamin D supplementation in this setting, so its exclusion was unlikely to affect the results. No increase in adverse events was noted with vitamin D supplementation.</p><p>The serum 25(OH)D level &lt;10 ng/mL (&lt;25 nmol/L) used as a threshold in the meta-analysis is well below the minimum level of 20 or 30 ng/mL (50 or 75 nmol/L) advised by national and international guidelines to prevent falls and fracture. Estimates of vitamin D requirements to achieve sufficient levels vary and depend in part upon sun exposure. The optimal intake of vitamin D to prevent deficiency is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2033.html" rel="external">"Overview of vitamin D"</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Optimal intake to prevent deficiency'</a>.)</p><p>Separate studies suggest that vitamin D supplementation prevents acute respiratory tract infections, particularly in patients who are vitamin D deficient, which might contribute to the benefit in preventing COPD exacerbations [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H3581997010"><span class="h1">INEFFECTIVE INTERVENTIONS</span></p><p class="headingAnchor" id="H2369943622"><span class="h2">Selective beta-blockers</span><span class="headingEndMark"> — </span>Preliminary data and a meta-analysis of 15 observational studies suggested that therapy with selective beta-blockers (given for comorbid cardiovascular disease) might reduce COPD exacerbations [<a href="#rid34">34-36</a>]. However, a randomized trial that included 532 patients with COPD and an increased risk of exacerbation (eg, moderate airflow limitation, exacerbation in the previous year, prescribed use of oxygen), but no cardiac indication for beta-blocker therapy, found that extended release <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> (25 to 100 mg/day) did not decrease the time to first exacerbation compared with placebo (hazard ratio 1.05, 95% CI 0.84 to 1.32) [<a href="#rid37">37</a>]. The study was stopped early for safety concerns. Metoprolol was associated with an increased risk of an exacerbation leading to hospitalization (hazard ratio 1.91, 95% CI 1.29 to 2.83), although the reason for this increase was unclear. There was no between group difference in forced expiratory volume in one second (FEV<sub>1</sub>). </p><p>Based on this study, selective beta-blockers do not have a role in prevention of COPD exacerbations but continue to be used for patients with a cardiovascular indication. (See  <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">"Management of the patient with COPD and cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H1865008741"><span class="h2">Statins</span><span class="headingEndMark"> — </span>Statins (hydroxymethylglutaryl [HMG] CoA reductase inhibitors) do not diminish COPD exacerbations, although they may have other health benefits. In observational studies of COPD, statins were associated with a reduced rate and severity of exacerbations, rate of hospitalizations, and mortality [<a href="#rid38">38-41</a>]. However, these beneficial effects were not supported in a trial that randomly assigned 885 participants with COPD, but without other indications or contraindications for statin therapy, to <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> 40 mg daily or placebo for up to 36 months [<a href="#rid42">42</a>]. Simvastatin did not reduce the rate of exacerbations or the time to first exacerbation. A systematic review found no clear benefit to statins in terms of lung function, exercise capacity, or mortality, but deemed evidence to be low quality [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H171223226"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122211.html" rel="external">"Society guideline links: Pulmonary rehabilitation"</a>.)</p><p class="headingAnchor" id="H1750081294"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/130880.html" rel="external">"Patient education: Pulmonary rehabilitation (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1616184636"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis after exacerbations</strong> – Chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased risk of mortality. For patients hospitalized with a COPD exacerbation, in-hospital mortality ranges from 3 to 9 percent and one-year mortality of approximately 25 percent. (See <a class="local">'Prognosis after an exacerbation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – Several general measures can help reduce the frequency of COPD exacerbations, including smoking cessation, pulmonary rehabilitation and increased physical activity, proper use of medications (including correct inhaler technique), and vaccination against seasonal influenza, SARS-CoV-2, and pneumococcus  (<a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 1</a>). (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic interventions</strong> – Most medications for COPD reduce the frequency of COPD exacerbations, including long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), inhaled glucocorticoids, and <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">roflumilast</a>. The selection among these medications is based on the patient’s severity of symptoms and risk of exacerbations and is discussed separately. (See <a class="local">'Optimizing medications for COPD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic </strong><strong>azithromycin</strong> – For patients with recurrent exacerbations (≥2 per year) despite optimal therapy with long-acting bronchodilator and glucocorticoid inhalers, prophylactic <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> may also reduce the frequency of exacerbations. (See <a class="local">'Prophylactic azithromycin'</a> above and  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease", section on 'Prophylactic macrolides'</a> and  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'For patients with frequent exacerbations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninvasive ventilation, for hypercapnic patients</strong> – For patients who require noninvasive ventilation (NIV) during a hospitalization for a COPD exacerbation and who remain hypercapnic, nocturnal NIV at home significantly reduces the risk of rehospitalization. (See <a class="local">'Noninvasive ventilation'</a> above and  <a class="medical medical_review" href="/z/d/html/1453.html" rel="external">"Nocturnal ventilatory support in COPD"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comprehensive discharge planning</strong> – After hospitalization for a COPD exacerbation, formal criteria for discharge and a comprehensive discharge plan may help to reduce readmissions and recurrent exacerbations after hospitalization for a COPD exacerbation  (<a class="graphic graphic_form graphicRef130525" href="/z/d/graphic/130525.html" rel="external">form 1</a>). (See <a class="local">'Comprehensive discharge planning'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Celli BR, Fabbri LM, Aaron SD, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021; 204:1251.</a></li><li><a class="nounderline abstract_t">Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011; 37:508.</a></li><li><a class="nounderline abstract_t">Çolak Y, Afzal S, Marott JL, et al. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. Respir Med 2019; 155:141.</a></li><li><a class="nounderline abstract_t">Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131:696.</a></li><li><a class="nounderline abstract_t">Roberts CM, Lowe D, Bucknall CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002; 57:137.</a></li><li><a class="nounderline abstract_t">Donaldson GC, Wedzicha JA. COPD exacerbations .1: Epidemiology. Thorax 2006; 61:164.</a></li><li><a class="nounderline abstract_t">Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154:959.</a></li><li><a class="nounderline abstract_t">Slenter RH, Sprooten RT, Kotz D, et al. Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration 2013; 85:15.</a></li><li><a class="nounderline abstract_t">Almagro P, Salvadó M, Garcia-Vidal C, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012; 84:36.</a></li><li><a class="nounderline abstract_t">Piquet J, Chavaillon JM, David P, et al. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J 2013; 42:946.</a></li><li><a class="nounderline abstract_t">Matkovic Z, Huerta A, Soler N, et al. Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease. Respiration 2012; 84:17.</a></li><li><a class="nounderline abstract_t">Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26:234.</a></li><li><a class="nounderline abstract_t">Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013; 10:81.</a></li><li><a class="nounderline abstract_t">Steriade AT, Johari S, Sargarovschi N, et al. Predictors of outcome of noninvasive ventilation in severe COPD exacerbation. BMC Pulm Med 2019; 19:131.</a></li><li><a class="nounderline abstract_t">Morton K, MacNeill S, Sanderson E, et al. Evaluation of 'care bundles' for patients with chronic obstructive pulmonary disease (COPD): a multisite study in the UK. BMJ Open Respir Res 2019; 6:e000425.</a></li><li><a class="nounderline abstract_t">Zafar MA, Panos RJ, Ko J, et al. Reliable adherence to a COPD care bundle mitigates system-level failures and reduces COPD readmissions: a system redesign using improvement science. BMJ Qual Saf 2017; 26:908.</a></li><li><a class="nounderline abstract_t">Atwood CE, Bhutani M, Ospina MB, et al. Optimizing COPD Acute Care Patient Outcomes Using a Standardized Transition Bundle and Care Coordinator: A Randomized Clinical Trial. Chest 2022; 162:321.</a></li><li><a class="nounderline abstract_t">Katajisto M, Koskela J, Lindqvist A, et al. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations. Respir Med 2015; 109:1320.</a></li><li><a class="nounderline abstract_t">Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med 2009; 24:457.</a></li><li><a class="nounderline abstract_t">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015; 147:894.</a></li><li><a class="nounderline abstract_t">Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016; 12:CD005305.</a></li><li><a class="nounderline abstract_t">Pradhan R, Lu S, Yin H, et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ 2022; 379:e071380.</a></li><li><a class="nounderline abstract_t">Foer D, Strasser ZH, Cui J, et al. Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes. Am J Respir Crit Care Med 2023; 208:1088.</a></li><li><a class="nounderline abstract_t">Rogliani P, Matera MG, Calzetta L, et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med 2019; 154:86.</a></li><li><a class="nounderline abstract_t">López-Cano C, Ciudin A, Sánchez E, et al. Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study. Diabetes 2022; 71:315.</a></li><li><a class="nounderline abstract_t">Barkas F, Anastasiou G, Milionis H, Liberopoulos E. Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials. Diabetol Int 2022; 13:325.</a></li><li><a class="nounderline abstract_t">Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012; 156:105.</a></li><li><a class="nounderline abstract_t">Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2015; 3:120.</a></li><li><a class="nounderline abstract_t">Rafiq R, Prins HJ, Boersma WG, et al. Effects of daily vitamin D supplementation on respiratory muscle strength and physical performance in vitamin D-deficient COPD patients: a pilot trial. Int J Chron Obstruct Pulmon Dis 2017; 12:2583.</a></li><li><a class="nounderline abstract_t">Zendedel A, Gholami M, Anbari K, et al. Effects of Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study. Glob J Health Sci 2015; 7:243.</a></li><li><a class="nounderline abstract_t">Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax 2019; 74:337.</a></li><li><a class="nounderline abstract_t">Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356:i6583.</a></li><li><a class="nounderline abstract_t">Du Q, Sun Y, Ding N, et al. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One 2014; 9:e113048.</a></li><li><a class="nounderline abstract_t">Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71:8.</a></li><li><a class="nounderline abstract_t">Suissa S, Ernst P. Beta-Blockers in COPD: A Methodological Review of the Observational Studies. COPD 2018; 15:520.</a></li><li><a class="nounderline abstract_t">Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med 2019; 381:2304.</a></li><li><a class="nounderline abstract_t">Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 2013; 126:598.</a></li><li><a class="nounderline abstract_t">Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009; 136:734.</a></li><li><a class="nounderline abstract_t">Sharif R, Parekh TM, Pierson KS, et al. Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11:685.</a></li><li><a class="nounderline abstract_t">Lawes CM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21:35.</a></li><li><a class="nounderline abstract_t">Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370:2201.</a></li><li><a class="nounderline abstract_t">Walsh A, Perrem L, Khashan AS, et al. Statins versus placebo for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2019.</a></li></ol></div><div id="topicVersionRevision">Topic 122145 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.goldcopd.org" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570991" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595157" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31362177" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognosis of COPD depends on severity of exacerbation history: A population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356082" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of COPD exacerbations on patient-centered outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11828043" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443707" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : COPD exacerbations .1: Epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8887592" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23037178" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21996555" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349446" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High-risk patients following hospitalisation for an acute exacerbation of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22327370" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055870" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Factors affecting survival of hospitalised patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23607835" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31319839" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Predictors of outcome of noninvasive ventilation in severe COPD exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31258918" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evaluation of 'care bundles' for patients with chronic obstructive pulmonary disease (COPD): a multisite study in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28733370" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reliable adherence to a COPD care bundle mitigates system-level failures and reduces COPD readmissions: a system redesign using improvement science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35405112" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Optimizing COPD Acute Care Patient Outcomes Using a Standardized Transition Bundle and Care Coordinator: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26298024" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194768" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25321320" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27930803" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36318979" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37647574" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31228775" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34737187" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34123693" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250141" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25476069" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28894361" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of daily vitamin D supplementation on respiratory muscle strength and physical performance in vitamin D-deficient COPD patients: a pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946929" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30630893" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28202713" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427000" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283710" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : β-Blockers are associated with a reduction in COPD exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30822238" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Beta-Blockers in COPD: A Methodological Review of the Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31633896" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Metoprolol for the Prevention of Acute Exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684060" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Statin use and risk of COPD exacerbation requiring hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19376844" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Statins in COPD: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24784958" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22218819" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Statin use in COPD patients is associated with a reduction in mortality: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836125" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Statins versus placebo for people with chronic obstructive pulmonary disease</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
